Handelsbanken Fonder AB Raises Holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Handelsbanken Fonder AB boosted its holdings in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) by 22.5% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 28,902 shares of the life sciences company’s stock after acquiring an additional 5,300 shares during the quarter. Handelsbanken Fonder AB’s holdings in Integra LifeSciences were worth $636,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Arrowstreet Capital Limited Partnership increased its position in shares of Integra LifeSciences by 7.1% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 13,756 shares of the life sciences company’s stock worth $312,000 after purchasing an additional 913 shares during the last quarter. Quadrant Capital Group LLC boosted its stake in Integra LifeSciences by 5,960.9% during the fourth quarter. Quadrant Capital Group LLC now owns 1,394 shares of the life sciences company’s stock worth $32,000 after buying an additional 1,371 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Integra LifeSciences by 3.9% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,466 shares of the life sciences company’s stock valued at $872,000 after acquiring an additional 1,437 shares during the last quarter. Sterling Capital Management LLC raised its stake in shares of Integra LifeSciences by 821.7% in the 4th quarter. Sterling Capital Management LLC now owns 2,166 shares of the life sciences company’s stock valued at $49,000 after acquiring an additional 1,931 shares during the period. Finally, Covestor Ltd lifted its holdings in shares of Integra LifeSciences by 61.8% in the 4th quarter. Covestor Ltd now owns 5,423 shares of the life sciences company’s stock worth $123,000 after acquiring an additional 2,071 shares during the last quarter. Hedge funds and other institutional investors own 84.78% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on IART. JMP Securities dropped their target price on shares of Integra LifeSciences from $35.00 to $25.00 and set a “market outperform” rating for the company in a report on Friday, May 9th. Wells Fargo & Company cut their price objective on Integra LifeSciences from $25.00 to $13.00 and set an “equal weight” rating on the stock in a report on Tuesday, May 6th. JPMorgan Chase & Co. lowered their target price on Integra LifeSciences from $24.00 to $12.00 and set an “underweight” rating for the company in a report on Tuesday, May 6th. Argus raised Integra LifeSciences from a “hold” rating to a “buy” rating in a research report on Monday, March 31st. Finally, Truist Financial reduced their price target on shares of Integra LifeSciences from $26.00 to $19.00 and set a “hold” rating on the stock in a research report on Friday, April 11th. Four analysts have rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $18.63.

Integra LifeSciences Stock Performance

Shares of IART opened at $12.16 on Monday. Integra LifeSciences Holdings Co. has a 1 year low of $11.60 and a 1 year high of $32.66. The stock has a market capitalization of $944.98 million, a PE ratio of -135.10, a PEG ratio of 0.73 and a beta of 1.16. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20. The stock has a 50-day simple moving average of $14.50 and a 200-day simple moving average of $20.18.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings results on Monday, May 5th. The life sciences company reported $0.41 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.43 by ($0.02). Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The firm had revenue of $382.65 million during the quarter, compared to analysts’ expectations of $381.17 million. During the same quarter in the prior year, the firm earned $0.55 EPS. The firm’s revenue was up 3.7% compared to the same quarter last year. On average, analysts predict that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current fiscal year.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.